Platelet survival time in patients with hypoxemia and pulmonary hypertension
- PMID: 837512
- DOI: 10.1161/01.cir.55.4.660
Platelet survival time in patients with hypoxemia and pulmonary hypertension
Abstract
Platelet survival time (autologous labeling with 51chromium) was measured in 63 patients in order to evaluate the role of platelets in the thromboembolic complications of patients with hypoxemia and pulmonary hypertension. Thirty-eight of these patients had chronic obstructive airways disease; 13, primary pulmonary hypertension; seven, recurrent pulmonary embolism; four, the Eisenmenger syndrome; and one, multiple pulmonary arteriovenous fistula. Forty-three patients were hypeakly associated with arterial oxygen tension ( r = 0.50), but not with the arterial carbon dioxide tension or the level of pulmonary artery pressure. Sulfinpyrazone lengthened platelet survival in 12 of 24 (50%) treated patients but this drug did not alter either arterial oxygen tension arterial carbon dioxide tension, or pulmonary artery pressure. Our results suggest that hypoxemia is associated with shortened platelet survival time and that platelets may, therefore, be involved in the thromboembolic complications that develop in patients with hypoxemia.
Similar articles
-
Platelet-mediated pulmonary hypertension and hypoxia during pulmonary microembolism: reduction by platelet inhibition.Chest. 1978 Dec;74(6):648-53. doi: 10.1378/chest.74.6.648. Chest. 1978. PMID: 738122
-
Effects of clofibrate and sulfinpyrazone on platelet survival time in coronary artery disease.Circulation. 1975 Sep;52(3):473-6. doi: 10.1161/01.cir.52.3.473. Circulation. 1975. PMID: 1157247
-
Platelets in rats with chronic normobaric hypoxic pulmonary hypertension.Respiration. 1985;48(2):159-63. doi: 10.1159/000194817. Respiration. 1985. PMID: 4059671
-
The role of platelets in the development and progression of pulmonary arterial hypertension.Adv Med Sci. 2018 Sep;63(2):312-316. doi: 10.1016/j.advms.2018.04.013. Epub 2018 Jun 7. Adv Med Sci. 2018. PMID: 29885631 Review.
-
Platelet inhibition in the management of thrombosis.Thromb Diath Haemorrh. 1974 Sep 30;32(1):21-34. Thromb Diath Haemorrh. 1974. PMID: 4616423 Review.
Cited by
-
KMA-Greenfield filter placement for chronic pulmonary hypertension.Ann Surg. 1979 May;189(5):560-5. doi: 10.1097/00000658-197905000-00004. Ann Surg. 1979. PMID: 443909 Free PMC article.
-
Dipyridamole treatment in chronic obstructive airways disease: effect on platelet regeneration time.Eur J Clin Pharmacol. 1982;23(5):423-7. doi: 10.1007/BF00605992. Eur J Clin Pharmacol. 1982. PMID: 7151846
-
Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.Thorax. 1999 Feb;54(2):161-8. doi: 10.1136/thx.54.2.161. Thorax. 1999. PMID: 10325923 Free PMC article. Review. No abstract available.
-
Antiplatelet agents: a review.J R Soc Med. 1979 Jul;72(7):513-9. doi: 10.1177/014107687907200710. J R Soc Med. 1979. PMID: 399644 Free PMC article. Review. No abstract available.
-
Biogenesis aberration: One of the mechanisms of thrombocytopenia in COVID-19.Front Physiol. 2023 Mar 20;14:1100997. doi: 10.3389/fphys.2023.1100997. eCollection 2023. Front Physiol. 2023. PMID: 37020458 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources